Amgen Inc. (AMGN)

317.45 -2.21 (-0.69%) At close: 04:00PM EDT

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 26,700

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Robert A. Bradway	Chairman, CEO & President	6.73M	N/A	1963
Mr. Peter H. Griffith	Executive VP & CFO	3.07M	N/A	1959
Mr. Esteban Santos	Executive Vice President of Operations	3.01M	N/A	1968
Dr. David M. Reese M.D.	Executive VP & CTO	3.4M	N/A	1963
Mr. Murdo Gordon	Executive Vice President of Global Commercial Operations	3.24M	N/A	1967
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance	N/A	N/A	1974
Dr. James E. Bradner M.D.	Executive VP of Research & Development and Chief Scientific Officer	N/A	N/A	1972
Justin G. Claeys	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Jonathan P. Graham	Executive VP, General Counsel & Secretary	2.44M	N/A	1961
Ms. Nancy A. Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	N/A	N/A	1968

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Corporate Governance

Amgen Inc.’s ISS Governance QualityScore as of October 1, 2024 is 2. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.